UTMB develops a universal vaccine platform that’s cheaper and shelf stable
Researchers at The University of Texas Medical Branch at Galveston have developed a less expensive way to produce vaccines that cuts the cost of vaccine production and storage by 80 percent without decreasing safety or effectiveness. The findings are currently available in EBioMedicine.
Vaccines are the most effective way to prevent and eradicate infectious diseases. Currently, many vaccines have to be manufactured in cell culture or eggs, which is expensive and carries the risk of contaminations. In addition, most vaccines must be kept refrigerated during the transportation from manufacturers to health care clinics. In tropical and subtropical regions, such cold storage requirements could contribute to more than 80 percent of the vaccine cost.
“The ability to eliminate cell culture or eggs and cold storage will change the process of vaccine development,” said UTMB’s Pei-Yong Shi, professor in the department of biochemistry and molecular biology. “Importantly, this vaccine technology could potentially serve as a universal platform for development of live-attenuated vaccines for many viral pathogens.”
To achieve these goals, the UTMB team engineered a live-attenuated Zika vaccine in the DNA form. Once the DNA is delivered into our body, it launches the vaccine in our cells, leading to antibody production and other protective immunity. With this production method, there is no need to manufacture the vaccine in cell culture or eggs at factories. Because DNA molecules are shelf stable, the vaccine will not expire at warm temperatures and could be stockpiled at room temperature for years.
Using UTMB’s Zika vaccine as a model, the research group showed that the DNA platform worked very efficiently in mice. After a single low dose, the DNA vaccine protected mice from Zika virus infection, mother-to-fetus transmission during pregnancy and male reproductive tract infection and damage.
“This is the first study to demonstrate that, after a single low dose, a DNA vaccine could induce saturated protective immunity,” Shi said. “We will continue testing this promising Zika vaccine platform and then apply the platform to other viruses.”
The Latest on: Vaccine production
via Google News
The Latest on: Vaccine production
- New Tech Could Make Coronavirus Vaccine in Record Timeon February 1, 2020 at 2:25 am
FILE - A staff member works at an egg testing workshop of Sinovac Biotech Ltd., a Chinese vaccine-making company, during the production of a vaccine for the H1N1 flu virus in Beijing, Nov. 19, 2009.
- Researchers make strides in race to create coronavirus vaccineon February 1, 2020 at 12:08 am
Researchers racing to produce a vaccine for the Wuhan coronavirus believe they may have taken significant steps towards finding an effective method of immunisation. At least three pharmaceutical ...
- J&J (JNJ) Plans to Develop Vaccine for New Coronaviruson January 31, 2020 at 5:35 pm
is looking to develop a vaccine for the new coronavirus infection. Its drug Erleada's label is expanded to include new prostate cancer patient population in Europe.
- Some Drugmakers Are Racing to Develop a Coronavirus Vaccine. Why Big Pharma Isn’t Rushing In.on January 31, 2020 at 7:59 am
Inovio Pharmaceuticals (INO) had a similar bump. These firms, along with Moderna (MRNA), are using newer vaccine technologies that could allow for the production and development of vaccines much ...
- Coronavirus Treatment and Vaccine Could Be a Step Closer Thanks to Antibody Which Can Neutralise 2019-nCoVon January 31, 2020 at 5:58 am
Scientists believe an antibody could soon help develop antiviral drugs and vaccines for the new and deadly Wuhan coronavirus, dubbed 2019-nCoV. Since the end of last year, the virus has killed 213 ...
- Pneumococcal Vaccines Market Witnessed To Take an Uptick in the Forecast Year 2026on January 31, 2020 at 3:20 am
A new market research report by Big Market Research on Pneumococcal Vaccines market reveals that the market is estimated to grow with a substantial growth rate from 2019-2026. This report is a ...
- Coronavirus vaccine research is moving at record speedon January 30, 2020 at 8:11 am
At Inovio, a biotech company headquartered outside Philadelphia, a team began working on designing a vaccine hours after the sequence appeared, said Shea, Inovio’s chief operating officer. The company ...
- Vaccines Market Worth $62.2 Billion by 2027 - Exclusive Report by Meticulous Research(R)on January 30, 2020 at 12:38 am
London, Jan. 30, 2020 (GLOBE NEWSWIRE) -- According to a new market research report "Vaccines Market by Indication (Influenza, Rotavirus, DTP Vaccines), Route of Administration (Intramuscular, ...
- J&J enters coronavirus fray with planned vaccineon January 29, 2020 at 11:11 am
The vaccine program will leverage Janssen's AdVac and PER.C6 technologies that provide the ability to rapidly upscale production, the same technologies behind its vaccines for Ebola, Zika, RSV and HIV ...
via Bing News